Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Halo Labs (OTCMKTS:WSLFF – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
Profitability
This table compares Milestone Pharmaceuticals and Halo Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Halo Labs | N/A | N/A | N/A |
Earnings and Valuation
This table compares Milestone Pharmaceuticals and Halo Labs”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $1.55 million | 84.74 | -$63.06 million | ($0.69) | -1.53 |
| Halo Labs | N/A | N/A | N/A | N/A | N/A |
Halo Labs has lower revenue, but higher earnings than Milestone Pharmaceuticals.
Insider & Institutional Ownership
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Milestone Pharmaceuticals and Halo Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
| Halo Labs | 0 | 0 | 0 | 0 | 0.00 |
Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 506.64%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Milestone Pharmaceuticals is more favorable than Halo Labs.
Summary
Milestone Pharmaceuticals beats Halo Labs on 7 of the 9 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
About Halo Labs
Westleaf Inc., an integrated cannabis company, engages in the cultivation, extraction, production, and retail sale of cannabis derivatives in Canada. It operates four retail stores under the Prairies Records name in Saskatchewan and Alberta, as well as an e-commerce operation in Saskatchewan. The company is headquartered in Calgary, Canada.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
